Valid for Submission
C56.3 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of bilateral ovaries. The code C56.3 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The code C56.3 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
New 2022 ICD-10 Code
C56.3 is new to ICD-10 code set for the FY 2022, effective October 1, 2021. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2021. This is a new and revised code for the FY 2022 (October 1, 2021 - September 30, 2022).
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|736||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC||13||4.2582|
|737||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC||13||2.0582|
|738||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC||13||1.4766|
|739||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC||13||3.8217|
|740||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC||13||1.8|
|741||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC||13||1.2795|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
C563 replaces the following previously assigned ICD-10 code(s):